Download - Incretin Therapy
![Page 1: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/1.jpg)
Role of Incretin in the management of diabetes
![Page 2: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/2.jpg)
![Page 3: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/3.jpg)
Outline
Core defect in Type 2 DM What is Incretin? Evidences Safety DPP4 Inhibitor GLP 1
![Page 4: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/4.jpg)
Defect in Type 2 DM
Three Hormone Theory
Insulin Deficiency,Glucagon Excess Decreased Incretin effect
Two Hormone TheoryInsulin Deficiency Glucagon Excess
One Hormone TheoryInsulin Deficiency
![Page 5: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/5.jpg)
![Page 6: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/6.jpg)
Multiple Defects Underlie the Pathophysiology of Type 2 Diabetes
ImpairedIncretin Effect
ImpairedIncretin Effect
Relative InsulinDeficiency
Relative InsulinDeficiency
InsulinResistance
InsulinResistance
Prediabetes and Type 2 Diabetes
Prediabetes and Type 2 Diabetes
Kendall DM, Cuddihy, RM, Bergenstal RM. Provided by David M. Kendall. MD.
![Page 7: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/7.jpg)
Pathophysiology of Type 2 Diabetes The Glucagon Factor• In response to a carbohydrate-containing meal,
individuals without diabetes not only increase insulin secretion but also simultaneously decrease pancreatic alpha-cell glucagon secretion.
• The decrease in glucagon is associated with a decrease in hepatic glucose production, and along with the insulin response, results in a very modest increase in postprandial glucose.
N Engl J Med. 1971;285:443-449.
![Page 8: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/8.jpg)
Pathophysiology of Type 2 Diabetes The Glucagon Factor• In contrast, the glucagon secretion in type 2 diabetics is
not decreased, and may even be paradoxically increased.
• These insulin and glucagon abnormalities produce an excessive postprandial glucose excursion.
N Engl J Med. 1971;285:443-449.
• More than 35 years ago, Roger Unger presciently stated,
"One wonders if the development of a pharmacologic means of suppressing glucagon to appropriate levels would increase the effectiveness of available treatments for diabetes”.
![Page 9: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/9.jpg)
Hepatic glucoseoutput
Insulin resistance
Glucose uptake
Glucagon(alpha cell)
Insulin(beta cell)
Pancreas
Liver
Hyperglycemia
Islet-cell dysfunction
Major Pathophysiologic Defects in Type 2 Diabetes1,2
Adapted with permission from Kahn CR, Saltiel AR. Joslin’s Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins; 2005:145–168.1. Del Prato S, Marchetti P. Horm Metab Res. 2004;36:775–781. 2. Porte D Jr, Kahn SE. Clin Invest Med. 1995;18:247–254.
MuscleAdipose tissue
![Page 10: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/10.jpg)
![Page 11: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/11.jpg)
![Page 12: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/12.jpg)
![Page 13: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/13.jpg)
![Page 14: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/14.jpg)
![Page 15: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/15.jpg)
Pathophysiology of Type 2 Diabetes The Gastric Emptying Factor
• Many factors can affect the rate of gastric emptying.
• Studies suggest that all other factors being equal, most people with type 1 and type 2 diabetes have accelerated gastric emptying compared to those without diabetes.
Gastroenterology. 1990;98:A378.
![Page 16: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/16.jpg)
Pathophysiology of Type 2 Diabetes
Another observation
• In 1930 La Barre described a greater effect of oral rather parenteral glucose in increasing insulin secretion.
• In 1986 Nauck demonstrated that a glucose infusion graded to achieve plasma glucose levels identical of those achieved with oral glucose led to a insulin response that was only one quarter as great.
J Clin Endocrinol Metab. 1986;63:492-498.
• Incretin hormones were discovered during researchers trials to find out interpretation to this phenomenon which has been called the incretin effect.
![Page 17: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/17.jpg)
![Page 18: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/18.jpg)
![Page 19: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/19.jpg)
Oral glucose load (50 g) IV glucose infusion
Pla
sma
gluc
ose
(mm
ol/L
)
–10 –5 60 120 180
10
Time (min)
5
0
15
Plasma glucose
90
0
180
270 Plasm
a glucose (mg
/dL)
The incretin hormones play a crucial role in a healthy insulin response
• Insulin response is greater following oral glucose than IV glucose, despite similar plasma glucose concentration
Insulin response
Insu
lin (
mU
/L)
80
60
40
20
–10 –5 60 120 1800
Time (min)
Incretineffect
Nauck et al. Diabetologia 1986;29:46–52, healthy volunteers (n=8)
![Page 20: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/20.jpg)
![Page 21: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/21.jpg)
![Page 22: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/22.jpg)
History of Incretins• Concept proposed in 1906 by Moore; secretin proposed as
gut hormone that enhanced postprandial insulin release• Term incretin introduced 1932 by LaBerre• Berson and Yalow developed RIA for insulin in 1960s, after
which several groups found plasma insulin levels were higher after PO than IV glucose when BG was the same
• Term entero-insular axis coined by Unger (1969)• GIP isolated by Brown in 1969 (Gastric Inhibitory Peptide)• GLP-1 (7-36) discovered in 1988 (Göke)• Term incretins (glucoincretins, insulinotrophic hormones)
today refer to hormones/peptides that reduce glucose excursions into blood after a meal via various mechanisms
![Page 23: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/23.jpg)
What are incretins?
• Hormones produced by the gastrointestinal tract in response to incoming nutrients, and have important actions that contribute to glucose homeostasis.
• Two hormones: Gastric inhibitory polypeptide (GIP) Glucagon-like peptide-1 (GLP-1).
INCRETIN= INtestinal+seCRETion of INsulin
![Page 24: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/24.jpg)
![Page 25: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/25.jpg)
GLP-1 and GIP Are Incretin Hormones
GLP-1 GIP Is released from L cells in ileum and
colon1,2
Is released from K cells in duodenum1,2
Stimulates insulin response from beta cells in a glucose-dependent manner1
Stimulates insulin response from beta cells in a glucose-dependent manner1
Inhibits gastric emptying1,2 Has minimal effects on gastric emptying2
Reduces food intake and body weight2
Has no significant effects on satiety or body weight2
Inhibits glucagon secretion from alpha cells in a glucose-dependent manner1
Does not appear to inhibit glucagon secretion from alpha cells1,2
1. Meier JJ et al. Best Pract Res Clin Endocrinol Metab. 2004;18:587–606. 2. Drucker DJ. Diabetes Care. 2003;26:2929–2940.
![Page 26: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/26.jpg)
The two primary incretin hormones are Glucagon-like Polypeptide -1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP)
• Circulating GIP and GLP-1 levels are regulated by multiple factors2
– Low in the basal fasting state; they rise rapidly following a meal from neuronal, neuroendocrine, and direct nutrient stimulation of intestinal cells
1Wei Y, et al. FEBS Lett 1995;358:219–224; 2Drucker DJ. Diabetes Care 2003;26:2929–2940.
GLP-1 GIP30 amino acid peptide1 42 amino acid peptide2
Synthesised and released by L cells of ileum and colon2
Synthesised and released from K cells of jejunum and duodenum2
Sites of action1:Pancreatic β-cells and α-cellsGI tractCNSLungsHeart
Sites of action2:Pancreatic β-cellsAdipocytes
![Page 27: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/27.jpg)
Incretin Physiology in Type 2 Diabetes Mellitus
GLP-1 & GIP Secretion inType 2 Diabetes Mellitus
![Page 28: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/28.jpg)
![Page 29: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/29.jpg)
0
5
10
15
20
0 60 120 180 240
Time after start of meal, minutes
GL
P-1
, p
mo
l/L
Type 2 diabetes, n=54
IGT, n=15
NGT, n=33
Decreased Postprandial Levels of the Incretin Hormone GLP-1 in Patients With Type 2 Diabetes
* * * * ** *
*P<0.05, Type 2 diabetes vs NGT. Reprinted with permission from Toft-Nielsen MB et al. J Clin Endocrinol Metab. 2001;86:3717–3723. Copyright © 2001, The Endocrine Society.
Meal Started
Meal Finished
(10-15)
![Page 30: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/30.jpg)
![Page 31: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/31.jpg)
Glucose-Dependent Insulinotropic Polypeptide (GIP) Response During OGTT
![Page 32: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/32.jpg)
Gastric Inhibitory Polypeptide (GIP) Insulinotrophic polypeptide
• Type 2 diabetes patients are resistant to its action (high blood level), making it a less attractive therapeutic target.
• In contrast to GLP-1 levels, plasma GIP is increased in patients with T2DM during an OGTT, while the plasma insulin response is diminished. This suggests resistance to the stimulator effect of GIP on insulin secretion and, in fact, this has been demon-strated by Holst et al.
• Jones IR, Owens DR, Luzio S, et al. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(9):668-677.
• Holst JJ, et al. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:199-206.
![Page 33: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/33.jpg)
![Page 34: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/34.jpg)
Insulin Secretion
β-Cell Neogenesis
β-Cell Apoptosis
Glucagon Secretion
Glucose Production
Heart
GI TractLiver
MuscleDrucker DJ. Cell Metab. 2006;3:153-165.
BrainAppetite
Cardioprotection
Cardiac Output GLP-1
Stomach
Gastric Emptying
Neuroprotection
Glucose Uptake
_
+
Summary of Pharmacologic Incretin Actions on Different Target Tissues
![Page 35: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/35.jpg)
GLP-1 modes of action in humans
GLP-1 is secretedfrom the L-cellsin the intestine
This in turn…
• Stimulates glucose-dependent insulin secretion
• Suppresses glucagon secretion
• Slows gastric emptying
Long term effectsdemonstrated in animals…
• Increases beta-cell mass and maintains beta-cell efficiency
• Improves insulin sensitivity
• Reduces food intake
Upon ingestion of food…
Drucker DJ. Curr Pharm Des 2001; 7:1399-1412Drucker DJ. Mol Endocrinol 2003; 17:161-171
EVIDENCE?
![Page 36: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/36.jpg)
GLP-1 effects are glucose-dependent in type 2 diabetes
Mean (SE); N = 10; *P < 0.05.Nauck MA, et al. Diabetologia 1993;36:741–744.
Glu
ca
go
n (
pm
ol/
L)300
200
100
0
Ins
uli
n (
pm
ol/
L)
Time (min)
-30 0 60 120 180 240
*** **
* **
Glu
co
se
(m
mo
l/L
)
15
10
5
0-30 0 60 120 180 240
*
*
*
*
* * *
Time (min)
-30 0 60 120 180 240
20
10
0
Time (min)
****
PBOGLP-1
PBOGLP-1
PBOGLP-1
Placebo (PBO)GLP-1
![Page 37: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/37.jpg)
![Page 38: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/38.jpg)
![Page 39: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/39.jpg)
![Page 40: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/40.jpg)
![Page 41: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/41.jpg)
![Page 42: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/42.jpg)
![Page 43: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/43.jpg)
![Page 44: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/44.jpg)
![Page 45: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/45.jpg)
Effect of GLP-1 (7-36)amide SC on Gastric Emptying
Subcutaneous injection of GLP-1 reduces the postmeal plasma glucose concentration, stimulates insulin secretion, and delays gastric emptying of a liquid meal.
![Page 46: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/46.jpg)
Exenatide Increases Gastric Half-Emptying Time (T50) for Solid Meal (Tc-Labeled Eggs)
Exenatide causes a dose-response inhibition of gastric emptying of a solid meal.
![Page 47: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/47.jpg)
![Page 48: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/48.jpg)
![Page 49: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/49.jpg)
![Page 50: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/50.jpg)
GLP-1 Regulates Central Feeding Behavior
Intracerebroventricular injection of GLP-1 causes a dose-response decrease in food intake in rats. As shown in the insert in the upper right, GLP-1 receptors are abundant in the paraventricuar nucleus of the hypothalamus and the central nucleus of the amygdala.
![Page 51: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/51.jpg)
Change in Body Weight Over 24 Weeks:Sitagliptin Monotherapy Studies
In a 24-week study, sitagliptin was shown to have no effect on body weight in patients with
T2DM.
![Page 52: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/52.jpg)
Sitagliptin + Pioglitazone Are Weight Neutral Compared to Pioglitazone Alone in T2DM
![Page 53: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/53.jpg)
![Page 54: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/54.jpg)
![Page 55: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/55.jpg)
![Page 56: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/56.jpg)
![Page 57: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/57.jpg)
![Page 58: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/58.jpg)
![Page 59: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/59.jpg)
![Page 60: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/60.jpg)
![Page 61: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/61.jpg)
![Page 62: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/62.jpg)
![Page 63: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/63.jpg)
![Page 64: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/64.jpg)
![Page 65: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/65.jpg)
![Page 66: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/66.jpg)
![Page 67: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/67.jpg)
![Page 68: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/68.jpg)
![Page 69: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/69.jpg)
![Page 70: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/70.jpg)
![Page 71: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/71.jpg)
![Page 72: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/72.jpg)
![Page 73: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/73.jpg)
![Page 74: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/74.jpg)
![Page 75: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/75.jpg)
![Page 76: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/76.jpg)
Actions of GLP-1 The Problem
• Unfortunately, GLP-1 is rapidly broken down by the DPP-IV enzyme (very short half-life in plasma - requires continuous IV infusion).
![Page 77: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/77.jpg)
The solution
Two options:
• Incretin mimetics are glucagon-like peptide-1 (GLP-1) agonists.
• Dipeptidyl peptidase-IV (DPP-IV) antagonists inhibit the breakdown of GLP-1.
![Page 78: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/78.jpg)
![Page 79: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/79.jpg)
What Is DPP-4?• A serine protease widely distributed throughout the body• Cleaves N-terminal amino acids of a number of biologically
active peptides, including the incretins GLP-1 and gastric inhibitory peptide (GIP), resulting in inactivation
• Its effects on GLP-1 and GIP have been shown to affect incretin activity
• Inactivates GLP-1 >50% in ~1 to 2 minutes
Ahrën B. Curr Enzyme Inhib. 2005;1:65-73.
![Page 80: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/80.jpg)
DPP-4
![Page 81: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/81.jpg)
Inhibition of DPP-4 Increases Active GLP-1
![Page 82: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/82.jpg)
GLP-1 and GIP Are Degraded by the DPP-4 Enzyme
Meal
Intestinal GIP and GLP-1 release
GIP and GLP-1 Actions
DPP-4Enzyme
GIP-(1–42)GLP-1(7–36)
Intact
GIP-(3–42)GLP-1(9–36)Metabolites
Rapid Inactivation
Half-life*GLP-1 ~ 2 minutes
GIP ~ 5 minutes
Deacon CF et al. Diabetes. 1995;44:1126–1131.*Meier JJ et al. Diabetes. 2004;53:654–662.
![Page 83: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/83.jpg)
Native GLP-1 is rapidly degraded by dipeptidyl peptidase 4 (DPP-4)
Human ileum, GLP-1 producingL-cells
Capillaries, DPP-4 (Di-Peptidyl Peptidase-4)
Double immunohistochemical staining for DPP-4 (red) and GLP-1 (green) in the human ileum
Adapted from: Hansen et al. Endocrinology 1999;140:5356–63
![Page 84: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/84.jpg)
Food intake
Stomach
GI tract
Intestine
Increases and prolongs GLP-1 effect on alpha-cells:
Alpha-cells
Pancreas
Insulin release
Net effect: Blood glucose
Beta-cells
Increases and prolongs GLP-1 and GIP effects on beta-cells:
DPP-4 inhibitor
Glucagon secretion
Incretins
DPP-4
DPP-4 Inhibitors Enhance Incretin and Insulin Secretion
Adapted from: Barnett A. Int J Clin Pract 2006;60:1454-70 Drucker DJ, Nauck MA. Nature 2006;368:1696-705Idris I, Donnelly R. Diabetes Obes Metab 2007;9:153-65
![Page 85: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/85.jpg)
![Page 86: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/86.jpg)
Dipeptidyl Peptidase-IV Antagonists Sitagliptin and Vildagliptin
• Sitagliptin and vildagliptin are the first agents in this class to have received FDA approval.
• Incidence of adverse reactions was reported to be very low in a pooled safety data from 5141 patients. ADA meeting, Chicago, June 2007.
• They are indicated as monotherapy and in combination with metformin, thiazolidinediones and insulin.
• They look to be at least weight neutral.
![Page 87: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/87.jpg)
![Page 88: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/88.jpg)
![Page 89: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/89.jpg)
![Page 90: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/90.jpg)
![Page 91: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/91.jpg)
![Page 92: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/92.jpg)
![Page 93: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/93.jpg)
![Page 94: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/94.jpg)
![Page 95: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/95.jpg)
![Page 96: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/96.jpg)
![Page 97: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/97.jpg)
![Page 98: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/98.jpg)
![Page 99: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/99.jpg)
Plasma Levels of Bioactive Intact GLP-1 (9-36)amide After Sitagliptin Administration in T2DM
![Page 100: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/100.jpg)
Sitagliptin Reduces Glucose AUC After a Glucose Load
![Page 101: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/101.jpg)
Sitagliptin Once Daily Improves Both Fasting and Postmeal Glucose Concentration
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. Aschner P, Kipnes MS, Lunceford JK, et al; Sitagliptin Study 021 Group
Part 3
![Page 102: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/102.jpg)
Sitagliptin Monotherapy and Coadministration With Metformin
Sitagliptin monotherapy and metformin monotherapy produce similar reductions in A1C in patients with T2DM and, when given in combination, provide an additive effect to reduce A1C.
![Page 103: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/103.jpg)
Sitagliptin: Proportion of Patients Achieving A1C Goals
Sitagliptin monotherapy and metformin monotherapy allow a similar percentage of participants with T2DM to achieve an A1C <7.0% and have an additive effect to reduce A1C to <7.0%.
![Page 104: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/104.jpg)
Sitagliptin: Active-Comparator (Glipizide) Add-on to Metformin
The addition of sitagliptin to metformin produces a similar decrease in A1C as the addition of glipizide to metformin over a 1-year period.
![Page 105: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/105.jpg)
Sitagliptin: Effect on Baseline A1C
The addition of sitagliptin to metformin produces a similar decrease in A1C, irrespective of the starting baseline A1C, as does the addition of glipizide to metformin over a 1-year period.
![Page 106: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/106.jpg)
Clinical Adverse Events in Active-Comparator Add-on to Metformin Study
Patients With Adverse Events, n (%) Sitagliptin 100 mg
(n=588) Glipizide (n=584)
One or more AEs 419 (71.3) 444 (76.0)
Drug-related AEs 85 (14.5) 177 (30.3)
Serious AEs (SAEs) 43 ( 7.3) 44 ( 7.5)
Serious drug-related AEs 0 ( 0.0) 2 ( 0.3)
Died 1 ( 0.2) 2 ( 0.3)
Discontinued due to AEs 16 ( 2.7) 21 ( 3.6)
Discontinued due to drug-related AEs
8 ( 1.4) 8 ( 1.4)
Discontinued due to SAEs 6 ( 1.0) 7 ( 1.2)
Discontinued due to serious drug-related AEs
0 ( 0.0) 0 ( 0.0)
Stein P. ADA 66th Scientific Sessions; June 9-14, 2006; Washington DC. Late-breaking abstracts.
Sitagliptin has an excellent safety profile and is associated with significantly fewer drug-related adverse events than glipizide.
![Page 107: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/107.jpg)
Sitagliptin and Measures of -Cell Function
Compared to placebo, sitagliptin therapy for 24 weeks reduced the proinsulin/insulin ratio and increased HOMA-beta, suggesting a beneficial effect on beta-cell function
![Page 108: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/108.jpg)
Sitagliptin: B-Cell Response to Glucose
During the frequently sampled meal tolerance test (MTT) performed before and after 18 weeks, sitagliptin significantly augmented insulin secretion compared to the placebo-treated group.
![Page 109: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/109.jpg)
Sitagliptin Studies: Summary1
As monotherapy, sitagliptin was as effective in reducing A1C as metformin and pioglitazone and was completely additive in decreasing A1C
when given to metformin-treated patients with T2DM.
![Page 110: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/110.jpg)
![Page 111: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/111.jpg)
![Page 112: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/112.jpg)
![Page 113: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/113.jpg)
![Page 114: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/114.jpg)
![Page 115: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/115.jpg)
![Page 116: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/116.jpg)
![Page 117: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/117.jpg)
Incretin mimetics
Exenatide
• The first incretin-related therapy available for patients with type 2 diabetes.
• Naturally occurring peptide from the saliva of the Gila Monster.
• Has an approximate 50% amino acid homology with GLP-1.
• Binds to GLP-1 receptors and behaves as GLP-1.
![Page 118: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/118.jpg)
![Page 119: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/119.jpg)
Incretin mimeticsExenatide
• Resistant to DPP-IV inactivation. Following injection, it is measurably present in plasma for up to 10 hours. Suitable for twice a day administration by subcutaneous injection.
Regul Pept. 2004;117:77-88.
Am J Health Syst Pharm. 2005;62:173-181.
![Page 120: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/120.jpg)
![Page 121: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/121.jpg)
![Page 122: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/122.jpg)
![Page 123: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/123.jpg)
![Page 124: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/124.jpg)
![Page 125: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/125.jpg)
![Page 126: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/126.jpg)
![Page 127: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/127.jpg)
![Page 128: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/128.jpg)
![Page 129: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/129.jpg)
![Page 130: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/130.jpg)
![Page 131: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/131.jpg)
![Page 132: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/132.jpg)
![Page 133: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/133.jpg)
![Page 134: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/134.jpg)
![Page 135: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/135.jpg)
![Page 136: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/136.jpg)
![Page 137: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/137.jpg)
![Page 138: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/138.jpg)
![Page 139: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/139.jpg)
![Page 140: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/140.jpg)
![Page 141: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/141.jpg)
ConclusionAs there is no proven link between use of incretin therapies and pancreatic cancer Diabetes UK does not advocate any change in its management. In particular, patients should NOT stop their medication unless advised to by their doctor. At the same time vigilance is required of patients on such therapies for any side effects suggestive of pancreatic disease. It also reminds clinicians and people with diabetes to be aware that incretin therapies are contraindicated in people with previous pancreatitis.
![Page 142: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/142.jpg)
At this time, patients should continue to take their medicine as directed until they talk to their health care professional, and health care professionals should continue to follow the prescribing recommendations in the drug labels.
![Page 143: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/143.jpg)
![Page 144: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/144.jpg)
The mean age of included individuals was 52 years, and 57.45% were male. Cases were significantly more likely than controls to have hypertriglyceridemia (12.92% vs 8.35%), alcohol use (3.23% vs 0.24%), gallstones (9.06% vs 1.34), tobacco abuse (16.39% vs 5.52%), obesity (19.62% vs 9.77%), biliary and pancreatic cancer (2.84% vs 0%), cystic fibrosis (0.79% vs 0%), and any neoplasm (29.94% vs 18.05%). After adjusting for available confounders and metformin hydrochloride use, current use of GLP-1–based therapies within 30 days (adjusted odds ratio, 2.24 [95% CI, 1.36-3.68]) and recent use past 30 days and less than 2 years (2.01 [1.37-3.18]) were associated with significantly increased odds of acute pancreatitis relative to the odds in nonusers.
![Page 145: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/145.jpg)
![Page 146: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/146.jpg)
![Page 147: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/147.jpg)
Considerations for Healthcare Professionals:•Be aware of the possibility for and monitor for the emergence of the signs and symptoms of pancreatitis such as nausea, vomiting, anorexia, and persistent severe abdominal pain, sometimes radiating to the back.•Discontinue sitagliptin or sitagliptin/metformin if pancreatitis is suspected.•Understand that if pancreatitis is suspected in a patient, supportive medical care should be instituted. The patient should be monitored closely with appropriate laboratory studies such as serum and urine amylase, amylase/creatinine clearance ratio, electrolytes, serum calcium, glucose, and lipase.•Inform patients of the signs and symptoms of acute pancreatitis so they are aware of and able to notify their healthcare professional if they experience any unusual signs or symptoms.
Advice:Health care person should honestly discuss with patient about risk of acute pancreatitis
![Page 148: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/148.jpg)
![Page 149: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/149.jpg)
The three organizations firmly believe that people taking these medications, or those who may consider taking them, should be informed of all that is currently known about their potential risks and advantages in order to make the best possible decisions about their treatment and care, in consultation with their health care providers. At this time, there is insufficient information to modify current treatment recommendations.
![Page 150: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/150.jpg)
![Page 151: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/151.jpg)
![Page 152: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/152.jpg)
![Page 153: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/153.jpg)
Old Antidiabetes drugs
Incretin
![Page 154: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/154.jpg)
![Page 155: Incretin Therapy](https://reader037.vdocuments.us/reader037/viewer/2022103113/554b3774b4c905da088b5573/html5/thumbnails/155.jpg)
Thank you